Intravenous iron administration and hypophosphatemia in clinical practice

International Journal of Rheumatology

Volumn 2015, Issue , 2015, Pages

  Hardy, S ^a   Vandemergel, X ^a  

^a Department of General Internal Medicine Centres Hospitaliers Jolimont ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON SACCHARATE; PHOSPHATE; VITAMIN D;

ADULT; ANEMIA; CREATININE BLOOD LEVEL; DISEASE DURATION; DISEASE SEVERITY; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; VITAMIN BLOOD LEVEL;

EID: 84929352912     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2015/468675     Document Type: Review

References (58)

1. A.C. Looker, P. R. Dallman, M. D. Carroll, E. W. Gunter, andC. L. Johnson, "Prevalence of iron deficiency in the United States," The Journal of the AmericanMedical Association, vol. 277, no. 12, pp. 973-976, 1997.
2. C. Cote, M. D. Zilberberg, S. H. Mody, L. J. Dordelly, and B. Celli, "Haemoglobin level and its clinical impact in a cohort of patients with COPD," European Respiratory Journal, vol. 29, no. 5, pp. 923-929, 2007.
3. B. J. Bryant, Y. Y. Yau, S. M. Arceo, J. A. Hopkins, and S. F. Leitman, "Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome," Transfusion, vol. 53, no. 8, pp. 1637-1644, 2013.
4. P. Vaucher, P.-L. Druais, S. Waldvogel, and B. Favrat, "Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: A randomized controlled trial," Canadian Medical Association Journal, vol. 184, no. 11, pp. 1247-1254, 2012.
5. S. Lindgren, O. Wikman, R. Befrits et al., "Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study," Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 838-845, 2009.
6. C. Bergwitz and H. Jüppner, "Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23," Annual Review of Medicine, vol. 61, pp. 91-104, 2010.
7. http://www.accessdata.fda.gov/drugsatfda docs/label /2013/203565s000lbl.pdf.
8. X. Vandemergel and F. Vandergheynst, "Potentially lifethreatening phosphate diabetes induced by ferric carboxymaltose injection: A case report and review of the literature," Case Reports in Endocrinology, vol. 2014, Article ID 843689, 5 pages, 2014.
9. A. Blazevic, J.M.Hunze, and J.M.M. Boots, "Severe hyposphosphatemia after intravenous iron administration," Netherlands Journal of Medicine, vol. 72, no. 1, pp. 49-53, 2014.
10. L.-Y. Mani, G. Nseir, J.-P. Venetz, and M. Pascual, "Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient," Transplantation, vol. 90, no. 7, pp. 804-805, 2010.
11. Y. C. Fierz, R. Kenmeni, A. Gonthier, F. Lier, F. Pralong, and P. Coti Bertrand, "Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient," European Journal of Clinical Nutrition, vol. 68, no. 4, pp. 531-533, 2014.
12. P.-Y. Liu and C.-Y. Jeng, "Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure," Journal of the Chinese Medical Association, vol. 67, no. 7, pp. 355-359, 2004.
13. S. B. De Oliveira Iglesias,H. Pons Leite, andW. B. De Carvalho, "Hypophosphatemia-induced seizure in a child with diabetic ketoacidosis," Pediatric Emergency Care, vol. 25, no. 12, pp. 859-861, 2009.
14. J. Turnbull, D. Lumsden, A. Siddiqui, J.-P. Lin, and M. Lim, "Osmotic demyelination syndrome associated with hypophosphataemia: 2 cases and a review of literature," Acta Paediatrica, vol. 102, no. 4, pp. e164-e168, 2013.
15. L. R. O'Connor, W. S. Wheeler, and J. E. Bethune, "Effect of hypophosphatemia on myocardial performance in man," The New England Journal of Medicine, vol. 297, no. 17, pp. 901-903, 1977.
16. A. Ognibene, R. Ciniglio, A. Greifenstein et al., "Ventricular tachycardia in acute myocardial infarction: The role of hypophosphatemia," SouthernMedical Journal, vol. 87, no. 1, pp. 65-69, 1994.
17. J. A. Russell, "Osteomalacic myopathy," Muscle and Nerve, vol. 17, no. 6, pp. 578-580, 1994.
18. P. C. Singhal, A. Kumar, L. Desroches, N. Gibbons, and J. Mattana, "Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia," American Journal ofMedicine, vol. 92, no. 5, pp. 458-464, 1992.
19. R. Poesen, D. Dierickx, and P. Evenepoel, "Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient," Transplant International, vol. 25, no. 2, pp. e27-e28, 2012.
20. J. L. Beard, "Iron biology in immune function, muscle metabolism and neuronal functioning," Journal of Nutrition, vol. 131, no. 2, pp. 568-580, 2001.
21. N. J. Kassebaum, R. Jasrasaria, M. Naghavi et al., "A systematic analysis of global anemia burden from1990 to 2010," Blood, vol. 123, no. 5, pp. 615-624, 2014.
22. R. P. Allen, S. Auerbach, H. Bahrain, M. Auerbach, and C. J. Earley, "The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia," The American Journal of Hematology, vol. 88, no. 4, pp. 261-264, 2013.
23. C. W. Wells, S. Lewis, J. R. Barton, and S. Corbett, "Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients," Inflammatory Bowel Diseases, vol. 12, no. 2, pp. 123-130, 2006.
24. L. E. Murray-Kolb, "Iron status and neuropsychological consequences in women of reproductive age: What do we know and where are we headed?" Journal of Nutrition, vol. 141, no. 4, pp. 747s-755s, 2011.
25. Q. Zhou, G. Lu, A. Liu, and T. Kohno, "Extraskeletal myxoid chondrosarcoma in the lung: Asymptomatic lung mass with severe anemia," Diagnostic Pathology, vol. 7, article 112, 2012.
26. J. M. Leung, R. B. Weiskopf, J. Feiner et al., "Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans," Anesthesiology, vol. 93, no. 4, pp. 1004-1010, 2000.
27. M. M. Wood and P. C. Elwood, "Symptoms of iron deficiency anaemia. A community survey," British Journal of Preventive & Social Medicine, vol. 20, no. 3, pp. 117-121, 1966.
28. B. Favrat, K. Balck, C. Breymann et al., "Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER a randomized, placebo-controlled study," PLoS ONE, vol. 9, no. 4,Article ID e94217, 2014.
29. R. Herfs, L. Fleitmann, and I. Kocsis, "Treatment of iron deficiency with or without anaemia with intravenous ferric carboxymaltose in gynaecological practices-A non-interventional study," Geburtshilfe und Frauenheilkunde, vol. 74, no. 1, pp. 81-88, 2014.
30. B. Froessler, J. Collingwood, N. A. Hodyl, and G. Dekker, "Intravenous ferric carboxymaltose for anaemia in pregnancy," BMC Pregnancy and Childbirth, vol. 14, article 115, 2014.
31. R. Evstatiev, O. Alexeeva, B. Bokemeyer et al., "Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease," Clinical Gastroenterology and Hepatology, vol. 11, no. 3, pp. 269-277, 2013.
32. D. B. van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione, "Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial," Obstetrics and Gynecology, vol. 110, no. 2, pp. 267-278, 2007.
33. L. T. Goodnough, D. B. Van Wyck, A. Mangione, J. Morrison, P. E. Hadley, and J. A. Jehle, "Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial," Transfusion, vol. 49, no. 12, pp. 2719-2728, 2009.
34. S. D. Anker, J. C. Colet, G. Filippatos et al., "Ferric carboxymaltose in patients with heart failure and iron deficiency," The New England Journal of Medicine, vol. 361, no. 25, pp. 2436-2448, 2009.
35. P. Ponikowski, D. J. van Veldhuisen, J. Comin-Colet et al., "Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency," European Heart Journal, vol. 36, no. 11, pp. 657-668, 2015.
36. W. Y. Qunibi, C.Martinez, M. Smith, J. Benjamin, A.Mangione, and S. D. Roger, "A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients," Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1599-1607, 2011.
37. C. Charytan, M. V. Bernardo, T. A. Koch, A. Butcher, D. Morris, and D. B. Bregman, "Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study," Nephrology Dialysis Transplantation, vol. 28, no. 4, pp. 953-964, 2013.
38. D. J. Cada, T. L. Levien, and D. E. Baker, "Ferric carboxymaltose," Hospital Pharmacy, vol. 49, no. 1, pp. 52-69, 2014.
39. Injectafer, American Regent, Shirley, NJ, USA, 2013.
40. I. Macdougall, A. H. Bock, F. Carrera et al., "FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia,"NephrologyDialysis Transplantation, vol. 29, no. 11, pp. 2075-2084, 2014.
41. O. Konijki, S. Fukaya, H. Kanou, T. Imamoura, T. Iwamoto, and M. Takasaki, "A case of hypophosphatemia induced by intravenous administration of saccharated ion oxide," Nihon Ronen Igakkai Zasshi, vol. 10, pp. 805-810, 1994.
42. Y. Shimizu, Y. Tada, M. Yamauchi et al., "Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia," Bone, vol. 45, no. 4, pp. 814-816, 2009.
43. T. Berndt and R. Kumar, "Phosphatonins and the regulation of phosphate homeostasis," Annual Review of Physiology, vol. 69, pp. 341-359, 2007.
44. T. Saito and S. Fukumoto, "Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism," International Journal of Pediatric Endocrinology, vol. 2009, Article ID 496514, 2009.
45. H. S. Murer, "Cellular mechanisms in proximal tubular Pi reabsorption: Some answers and more questions," Journal of the American Society of Nephrology, vol. 2, no. 12, pp. 1649-1665, 1992.
46. M. Wolf, T. A. Koch, and D. B. Bregman, "Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women," Journal of Bone and Mineral Research, vol. 28, no. 8, pp. 1793-1803, 2013.
47. B. H. Durham, F. Joseph, L. M. Bailey, and W. D. Fraser, "The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays," Annals of Clinical Biochemistry, vol. 44, no. 5, pp. 463-466, 2007.
48. B. J. Schouten, P. J. Hunt, J. H. Livesey, C. M. Frampton, and S. G. Soule, "FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study," Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2332-2337, 2009.
49. M. Prats, R. Font, C. García, C. Cabré, M. Jariod, and A. M. Vea, "Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: Post-hoc analysis of a prospective study," BMC Nephrology, vol. 14, article 167, 2013.
50. H. Wang, Y. Yoshiko, R. Yamamoto et al., "Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation andmatrix mineralization in vitro," Journal of Bone andMineral Research, vol. 23, no. 6, pp. 939-948, 2008.
51. K. Sato and M. Shiraki, "Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy," Endocrine Journal, vol. 45, no. 4, pp. 431-439, 1998.
52. S. Yamamoto, Y. Okada, H. Mori, S. Fukumoto, and Y. Tanaka, "Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide," Internal Medicine, vol. 51, no. 17, pp. 2375-2378, 2012.
53. S. E. Williams, "Metabolic bone disease in the bariatric surgery patient," Journal of Obesity, vol. 2011, Article ID 634614, 9 pages, 2011.
54. S. E. Williams and A. A. Licata, "Improved forearm bone mineral density after treatment with vitamin D3 in a patient 30 years after bariatric surgery," Journal of Bone and Mineral Research, vol. 23, article s226, 2008.
55. Z. H. Hoo and M. J. Wildman, "Intravenous iron among cystic fibrosis patients," Journal of Cystic Fibrosis, vol. 11,no. 6, pp. 560-562, 2012.
56. A.Martin-Malo, A.Merino, J. Carracedo et al., "Effects of intravenous iron on mononuclear cells during the haemodialysis session," Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2465-2471, 2012.
57. R. Kumar, "Tumor-induced osteomalacia and the regulation of phosphate homeostasis," Bone, vol. 27, no. 3, pp. 333-338, 2000.
58. G. I. Baroncelli, B. Toschi, and S. Bertelloni, "Hypophosphatemic rickets," Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 6, pp. 460-467, 2012.